All In Biotech

Drug Trial Radar · NCT00434993

Drug Study of Albuterol to Treat Acute Lung Injury

Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury

Last checked: Nov 20, 2026Latest source record: Feb 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

282

Actual

Start

Aug 2007

Primary completion

Sep 2008

Study completion Nov 2008

Sponsor

Sponsor type
NIH
First posted
Feb 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.

Conditions

  • Respiratory Distress Syndrome, Adult

Interventions

  • Albuterol SulfateDrug

    Albuterol sulfate, USP, solution for inhalation will be diluted as follows: * The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution. * The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution. A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.

  • Mini-Bronchoalveolar Lavage (BAL)Procedure

    The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3

  • PlaceboDrug

    Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative. A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle). The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Ventilator Free Days (VFD)Time frame: Determined 28 days after a subject entered the study

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • University of San Francisco-Fresno Medical Center

    Fresno, California

  • University of California, Davis Medical Center

    Sacramento, California

  • UCSF-Moffitt Hospital

    San Francisco, California

  • UCSF-San Francisco General Hospital

    San Francisco, California

  • Centura St. Anthony Central Hospital

    Denver, Colorado

  • Denver Health Medical Center

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • University of Colorado Health Sciences Center

    Denver, Colorado

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Baton Rouge General Hospital-Blue Bonnet

    Baton Rouge, Louisiana

  • Baton Rouge General Hospital-Midcity

    Baton Rouge, Louisiana

  • Earl K. Long Medical Center

    Baton Rouge, Louisiana

  • Our Lady of the Lake Regional Medical Center

    Baton Rouge, Louisiana

  • Medical Center of Louisiana

    New Orleans, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Baltimore VA Medical Center

    Baltimore, Maryland

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • University of Maryland Shock Trauma Center

    Baltimore, Maryland

  • Baystate Medical Center

    Springfield, Massachusetts

  • Rochester Methodist Hospital

    Rochester, Minnesota

  • St. Mary's Hospital, Mayo Clinic

    Rochester, Minnesota

  • University of North Carolina

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Durham Regional Medical Center

    Durham, North Carolina

  • Moses Cone Health System

    Greensboro, North Carolina

  • Wesley Long Community Hospital

    Greensboro, North Carolina

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • MetroHealth Medical Center

    Cleveland, Ohio

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • McKay-Dee Hospital

    Ogden, Utah

  • Utah Valley Regional Medical Center

    Provo, Utah

  • LDS Hospital

    Salt Lake City, Utah

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Harborview Medical Center

    Seattle, Washington

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.